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Abstract Human L-defensin 2 (HBD2), an antimicrobial pep-
tide, is widely expressed in epithelial tissues and displays a
potent killing activity in response to the invasiveness of a wide
range of microorganisms and the stimulation of various mole-
cules. Myeloid ELF-1-like factor (MEF) has been reported to
be involved in innate immunity responses, such as activation of
perforin and lysozyme transcription. The role of MEF in the
transcription regulation of HBD2, however, is unknown. Here,
we show that MEF not only activated HBD2 promoter activity,
but also increased the endogenous HBD2 transcription level.
Moreover, the activated HBD2 promoter activity was attenu-
ated by the antisense MEF RNA input and the loss of the ETS
binding site (EBS: GGAA core sequence) in the HBD2 pro-
moter. The interaction between the EBS and MEF protein
was further con¢rmed by electrophoretic mobility shift assay.
Thus, our data indicate that MEF may play an important role
in regulating HBD2 expression in epithelial cells.
0 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: Myeloid ELF-1-like factor; Human L-defensin 2;
ETS binding site
1. Introduction
Antimicrobial molecules secreted by various tissues consti-
tute an essential component of innate immunity [1,2]. Defen-
sins are extensively characterized antimicrobial peptides and
have a broad spectrum of antimicrobial activity against bac-
teria, yeasts and fungi. Defensins are divided into K- and L-
defensin subfamilies according to the positions of six highly
conserved cysteine residues that participate in disul¢de link-
ages [3]. Among the four human L-defensins (HBD1^4) char-
acterized in various epithelial tissues, HBD2 is detected in
epithelial cells of the skin, lung, gingiva, trachea and repro-
ductive tract. Its expression is inducible in response to the
invasiveness of yeast and both Gram-negative and Gram-pos-
itive bacteria [4,5], and stimulation by lipopolysaccharide [6^
8] and a number of proin£ammatory cytokines [9^12]. Multi-
ple pathways, including the NF-UB pathway [4^6,13] and the
mitogen-activated protein kinase pathway [14,15], have been
reported to be involved in HBD2 regulation.
Genomic analysis of HBD2 revealed a promoter region
containing several putative transcription factor binding sites,
including NF-UB, activator protein (AP)-1, AP-2, and NF-
interleukin (IL)-6, which are known to be involved in the
regulation of in£ammatory responses [9]. Additionally, the
putative binding site (core sequence GGAA) of ETS transcrip-
tion factors (EBS) was also identi¢ed in this promoter, but it
has not been investigated whether the ETS family of tran-
scriptional factors is involved in HBD2 regulation.
The ETS family of transcription factors is characterized by
an 85-amino-acid ETS domain that recognizes a core sequence
GGAA or TTCC and thereby speci¢cally binds to DNA [16].
The ETS family of transcription factors plays important roles
in the development and function of multiple mammalian cell
types. Its functions in epithelial cells have been a subject of
active recent investigations. Myeloid ELF-1-like factor
(MEF), an ETS transcriptional factor [17], is located on chro-
mosome Xq26.1 with an observed protein size about 98 kDa.
It has potent transcriptional activating e¡ects on genes ex-
pressed in both lymphoid and myeloid cells. A study by Miya-
zaki et al. [18] demonstrated that the transcriptional activity
of MEF varies during di¡erent phases of the cell cycle in
hematopoietic cells. MEF not only possesses tumor-suppres-
sive capability through inhibiting the transcription of some
tumorigenic factors, such as matrix metalloproteinase
(MMP)-9 and IL-8 [19], but also plays an essential role in
innate immunity. It is required in epithelial cells to regulate
the expression of lysozyme, which is an important component
of innate immunity against common pathogens [20]. Further-
more, MEF also directly transactivates perforin in NK cells.
MEF3/3 mice have a profound reduction in the number of
NK-T and NK cells. Puri¢ed MEF3/3 NK cells secrete only
minimal amounts of interferon-Q and cannot be targeted to
tumor. These facts indicate a speci¢c role of MEF in the
development and function of NK cells and in innate immunity
[21].
In this study, we sought to investigate whether MEF a¡ects
the transcriptional activity and expression of HBD2 in human
epithelial cells. Our results indicate that MEF is a potential
activating factor for transcriptional regulation of HBD2.
2. Materials and methods
2.1. Cell culture
A549 cells (human pulmonary adenocarcinoma cells), stably MEF-
transfected A549 cells, NIH3T3 cells (mouse ¢broblast cells) and
HEK293 cells (human kidney cells) were grown in Dulbecco’s modi-
¢ed Eagle’s medium supplemented with 10% fetal bovine serum at
37‡C in a humidi¢ed 5% CO2 and 95% air atmosphere.
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HeLa cells (human cervical adenocarcinoma cells) were grown in
minimum essential medium supplemented with 10% fetal bovine se-
rum at 37‡C in a humidi¢ed 5% CO2 and 95% air atmosphere.
2.2. Preparation of plasmid DNA
HBD2(3247) was cloned by PCR using a Genome Walker Kit
(Clontech). A 5P primer, HBD2(3247), and a 3P primer, HBD2-
(+22+44), were used for polymerase chain reaction (PCR). The
PCR product was cloned into pCR2.1 vector using the Original TA
cloning kit (Invitrogen). After con¢rming the sequence, it was cloned
into the SacI and XhoI sites of pGL2-basic vector, a promoter-less
luciferase expression plasmid.
HBD2(3247)mut is a wild type HBD2(3247) construct with a mu-
tant EBS. It was created from HBD2(3247) using a Transformer site-
directed mutagenesis kit (Clontech). A mutation primer,
HBD2(3247)mut, which contains a mutant EBS, and a selection
primer, Trans Oligo ScaI/StuI, were used.
HBD2(389) was prepared by PCR using HBD2(3247) as a tem-
plate. A 5P primer, HBD2(389)XhoI, and a 3P primer, HBD2-
(+22+44), were used. The PCR product was cloned into the XhoI sites
of pGL2-basic vector.
The sequences of primers used in this study are shown in Table 1.
The expressing vectors of ETS family transcription factors and
antisense MEF were prepared as previously described [20]. They
were cloned into mammalian expression vector pCB6.
2.3. Transfection and luciferase assay
Transient transfections of plasmid DNA were performed with
TransIT-LT1 (Panvera) according to the manufacturer’s recommen-
dations. Brie£y, TransIT-LT1 and Opti-MEM were mixed thoroughly
and incubated at room temperature for 15 min. Then DNA was
added to the diluted TransIT-LT1 reagent (ratio: 1 Wg DNA/3 Wl
LT1). After being mixed gently, the mixture was incubated at room
temperature for 15 min. Then the mixture was directly added to the
cells cultured on 24-well plates, without changing the medium. Forty-
eight hours after transfection, the medium was removed and cells were
harvested for luciferase assay. Cotransfection of the pRL-CMV
(Promega), which expresses Renilla luciferase, veri¢ed that di¡erences
in ¢re£y luciferase reporter gene expression were not due to di¡er-
ences in transfection e⁄ciency. Luciferase activity was measured as
previously described [20]. Values are shown as meansSS.E.M. (n=4).
To normalize expression levels of the transcription factors, we mea-
sured mRNA by Northern blotting using the transcribed sequence of
pCB6 as a probe.
2.4. RNA preparation and reverse transcription (RT)-PCR
Isogen (Nippon Gene) was used for extracting total RNA from cells
according to the manufacturer’s instructions. The concentration of
total RNA obtained above was determined by measuring the UV
absorbance (260 nm). RNA with high purity (OD260/OD280v 1.80)
was used for experiments.
A549 cells and stably or transiently MEF-transfected A549 cells
were grown to about full con£uence after 48 h incubation. Cells
were harvested and total RNA was extracted. RT-PCR was per-
formed with 0.5 Wg RNA using a RNA PCR kit (Takara) according
to the manufacturer’s instructions: 30‡C for 10 min, 42‡C for 60 min,
99‡C for 5 min, and 5‡C for 5 min for reverse transcription; 95‡C for
1 min, 60‡C for 1 min, 72‡C for 1.5 min, 40 cycles. Primers HBD2-1A
and HBD2-1S were used. Expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was checked as an internal control. The 5P
primer GAPDH-up and the 3P primer GAPDH-down were used.
2.5. Western blotting
Whole cell lysates were subjected to sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis using 7.5% gel, then the proteins were
transferred to a polyvinylidene di£uoride membrane. After blocking
with 5% skim milk at 4‡C overnight, membranes were incubated with
a⁄nity-puri¢ed rabbit antisera to MEF (1/200; TransGenic) at room
temperature for 2 h. The membranes were subsequently incubated
with horseradish peroxidase-conjugated goat anti-rabbit IgG (1/
10 000; Seikagaku) at room temperature for 1 h. Finally chemilumi-
nescence was detected using the ECL kit (Amersham Life Science).
2.6. Preparation of nuclear extract
A549 cells (1U106) were washed, collected and pelleted with phos-
phate-bu¡ered saline by centrifugation at 1500Ug for 5 min, at 4‡C.
The pellet was resuspended in 400 Wl of cold bu¡er containing 10 mM
HEPES-KOH (pH 7.9), 10 mM KCl, 0.1 mM EDTA (pH 8.0), 0.1
mM EGTA (pH 8.0), 1 mM dithiothreitol and 0.5 mM phenylmeth-
ylsulfonyl £uoride by gentle pipetting. The cells were then allowed to
swell on ice for 15 min, after which 25 Wl of 10% Nonidet P-40 solu-
tion was added, and the tube was vigorously vortexed for 10 s. The
homogenate was centrifuged at 15 000 rpm for 1 min, at 4‡C. The
nuclear pellet was resuspended in 50 Wl of ice-cold bu¡er containing
20 mM HEPES-KOH (pH 7.9), 0.4 M NaCl, 1 mM EDTA (pH 8.0),
1 mM EGTA (pH 8.0), 1 mM dithiothreitol and 1 mM phenylmeth-
ylsulfonyl £uoride, the tube was vigorously vortexed for 15 min at
4‡C. Then the nuclear extract was centrifuged at 15 000 rpm for 5 min,
at 4‡C and the clear supernatant was collected, quickly frozen in liq-
uid nitrogen, and stored at 380‡C until further use. Protein concen-
tration was determined using the Bradford assay (Bio-Rad) and bo-
vine serum albumin as standard (Sigma).
2.7. Electrophoretic mobility shift assay (EMSA)
The double-stranded oligonucleotides EBS(wt), EBS(mut), and EB-
S(mut*) were synthesized for use in the EMSA experiments. The sense
sequences of each pair are listed in Fig. 4A. The probe EBS(wt) was
labeled with [Q-32P]ATP (22 TBq/mmol) using T4 polynucleotide ki-
nase (Takara). Pre-incubation of 5^10 Wg nuclear extract with 2 Wg
poly(dI-dC) (Amersham Pharmacia Biotech), excess unlabeled
EBS(wt), EBS(mut) or EBS(mut*), antibody to MEF or ETS2 (Santa
Cruz Biotechnology) or ESE2 (Santa Cruz Biotechnology) was carried
out on ice for 30 min in bu¡er containing 10 mM Tris^HCl (pH 7.5),
50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.05% Nonidet P-
40, 5% glycerol and 1 mg/ml bovine serum albumin. Radiolabeled
oligonucleotide probes (0.04 pmol, 5U104 cpm) were then added to
the reaction mixtures and incubated at room temperature for 30 min.
The reaction products were then analyzed by electrophoresis on a
5.5% polyacrylamide gel, followed by BAS2000.
3. Results
3.1. MEF up-regulates HBD2 promoter activity
HBD2(3247), the promoter construct we used, contains the
main elements responsive to in£ammatory factors and the
EBS (Fig. 1A). To determine the role of MEF in HBD2 reg-
ulation, we ¢rst examined the e¡ects of expressing ETS factors
on HBD2(3247) promoter activity in the human lung epithe-
lial cell line A549. MEF activated the HBD2(3247) promoter
more strongly than the other ETS factors in A549 cells (Fig.
1B). A similar result was also observed in HeLa cells. In
addition, in the mouse ¢broblast cell line (NIH3T3) (Fig.
1C), which does not endogenously express MEF, MEF trans-
fection induced much higher HBD2(3247) activity. The pos-
itive involvement of MEF was further con¢rmed by transfect-
ing the antisense MEF RNA construct, which blocked the
endogenous MEF. As shown in Fig. 1D,E, HBD2(3247)
transactivity was inhibited by transfecting antisense MEF
RNA into stably MEF-transfected A549 or HEK293 cells,
which have a high background of MEF expression. The e⁄-
Table 1
Sequences of oligonucleotides used for PCR, RT-PCR
Name Sequence (5P-3P)
HBD2(3247) GAGGAATTTTCTGGTCCCAAG
HBD2(3247)mut AAGAGCAGGAGCTAGGGATTTTCT
HBD2(389)XhoI CCGCTCGAGAATACCAGTTCTGAACTCTA
HBD2(+22+44) CCATGAGGGTCTTGTATCTCCTC
Trans Oligo ScaI/StuI GTGACTGGTGAGGCCTCAACCAAGTC
HBD2-1A GGAGCCCTTTCTGAATCCGCA
HBD2-1S CCCAGCCATCAGCCATGAGGGT
GAPDH-up GGAGCATGTGAATGCCATC
GAPDH-down GGATGACAAGCAGAAAGTC
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ciency of DNA transfection and MEF expression levels in
each cell line were examined by Western blotting (Fig. 1F).
3.2. MEF up-regulates endogenous HBD2 expression
To test the e¡ect of MEF on the endogenous transcription
level of HBD2, we investigated the HBD2 mRNA level in
transiently and stably MEF-transfected A549 cells (Fig. 2).
Both of them showed a higher HBD2 mRNA level than un-
transfected A549 cells, suggesting that MEF also mediates the
transactivation of the endogenous HBD2 gene in A549 cells.
3.3. The transactivity of MEF on HBD2 promoter is
EBS-dependent
The experimental results shown above indicate that MEF
up-regulates HBD2 proximal promoter activity. To investigate
whether the EBS in HBD2(3247) is involved in MEF regu-
lation, we ¢rst developed a shorter promoter construct,
HBD2(389), in which EBS was deleted. Interestingly, MEF
no longer potently transactivated its promoter activity (Fig.
3A). Next, we introduced nucleotide mutations into EBS in
HBD2(3247) and then compared the transactivity of MEF on
this mutant promoter and wild type promoter. As shown in
Fig. 3B, MEF increased wild type HBD2(3247) activity in a
dose-dependent manner, and this increase was greatly attenu-
ated by the loss of EBS, indicating that MEF may exert its
transactivity by binding to the EBS in HBD2(3247). It should
be noted that MEF still retained some transactivating ability
on HBD2(3247)mut, although to a lesser extent in compar-
ison with wild type construct. Thus, it is likely that MEF may
simultaneously regulate this promoter through other uniden-
ti¢ed mechanism(s).
3.4. MEF binds to EBS in HBD2 promoter
Having demonstrated its ability to transactivate HBD2 pro-
Fig. 2. HBD2 mRNA levels in original A549 cells and stably and
transiently MEF-transfected A549 cells. RT-PCR was performed ac-
cording to the manufacturer’s instructions (RNA PCR kit, Takara).
Fig. 1. MEF up-regulates HBD2 promoter activity. A: Schematic
representation of HBD2(3247) containing the indicated putative cis-
elements. B^E: A549 cells, stably MEF-transfected A549 cells,
HeLa cells, NIH-3T3 cells and HEK293 cells were transiently trans-
fected with the HBD2 promoter construct HBD2(3247) (0.2 Wg/
well) and the indicated ETS transcription factors (0.4 Wg/well, if the
DNA amount is not indicated in the ¢gure) or antisense MEF (0.4
Wg/well), using TransIT-LT1. Forty-eight hours after transfection,
cells were harvested for luciferase assay. The fold transactivity of
HBD2(3247) with empty pCB6 is assigned the value of 1 (open
bars). F: MEF expression at protein level was examined by Western
blotting in di¡erent cells. For transient transfection, A549 cells were
transfected with DNA (indicated at the top of each panel) using
TransIT-LT1 at the ratio 1 Wg DNA/3 Wl LT1 in 6-well plates. The
stably MEF-transfected A549 cells are indicated as MEF-stable. A
non-speci¢c band (NS) serves as a loading control.
Fig. 3. MEF loses transcriptional activity on HBD2 promoter with-
out EBS. A549 cells were transiently transfected with the HBD2
promoter construct HBD2(3247) or HBD2(389) (0.2 Wg/well) and
MEF (0.4Wg/well, if the DNA amount is not indicated in the ¢gure)
using TransIT-LT1. Forty-eight hours after transfection, cells were
harvested for luciferase assay.
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moter activity, we next examined whether MEF protein di-
rectly interacts with the proximal EBS by using the Q-32P-
labeled HBD2 promoter sequence EBS(wt) as a probe (Fig.
4A), which contains intact EBS. EMSA (Fig. 4B) indicated
that the upper band resulted from the binding between MEF
protein and probe, because the antibody against MEF atte-
nuated this band. The interaction of the polyclonal antibody
with MEF protein may interfere with the binding of MEF
with probe DNA, so that the supershifted band could not
be observed. The lower bands are supposed to correspond
to other ETS family factors competing for the EBS or some
proteins having a⁄nity to the probe sequence, because these
bands became stronger after the MEF binding was blocked by
its antibody. The antibodies to ETS2 and ESE2, used as con-
trols, had no e¡ect on any of these bands. In addition, we also
performed the competitor assay using unlabeled probe se-
quence HBD(wt) and sequences with EBS mutations, EB-
S(mut) and EBS(mut*) (Fig. 4C). In EBS(mut*), besides the
identi¢ed EBS, the other two sites similar to the EBS se-
quence, GGAG and GGAT, were also mutated (Fig. 4A).
Compared to EBS(mut) and EBS(mut*), unlabeled EBS(wt)
attenuated the upper band more strongly, thereby con¢rming
the binding between the probe with wild type EBS and MEF
protein.
4. Discussion
Defensins comprise a group of biological e¡ectors, which
can protect various tissues from microbial invasion and infec-
tion through direct killing as well as recruiting immune cells
(T cells and dendritic cells). Thus defensins play a critical role
in the innate immunity system and the link between innate
and acquired immunities. Among the defensin family, the in-
duction of HBD2 has been extensively studied recently. A
variety of exogenous stimuli and physiological factors have
been shown to induce HBD2. The NF-UB pathway appears
to be the best-known pathway involved in transducing these
signals to the transcriptional regulation of HBD2 [6,22]. In
addition, it is reported that AP-1 and intracellular calcium
are also involved in HBD2 expression in airway epithelial cells
[23].
The data presented here indicate MEF enhanced not only
HBD2 promoter activity but also its endogenous transcrip-
tion. In support of this notion, expressing antisense MEF
RNA attenuated HBD2 promoter activity in both stably
MEF-transfected cells and those without exogenous input of
MEF. Furthermore, the EBS in HBD2 promoter appears to
be essential for its binding with MEF protein and the conse-
quent promoter transactivation. Together, these results indi-
cate that MEF acts as a novel transactivator of HBD2 in
epithelial cells, which functions through a mechanism inde-
pendent of NF-UB. Thus MEF may have the potential to
enhance basic HBD2 expression under non-irritated physio-
logical conditions.
MEF belongs to the ETS transcription factor family, which
plays an important role in cell growth, death and di¡erentia-
tion. It was revealed to suppress the promoter activities of
MMP-9 and IL-8 genes, thus was thought to be a tumor
suppressor gene that is down-regulated by methylation in can-
cer cells [19]. Although MEF constitutively localizes in the
nucleus [24], its activity may vary under di¡erent circumstan-
ces or in di¡erent cell contexts. A recent study suggested that,
in hematopoietic cells, its transcriptional activity was largely
restricted to the G1 phase of the cell cycle [18]. This phenom-
enon is due to its change in phosphorylation status, which
may also occur in epithelial cells. Our study also indicates
that MEF may respond to some exogenous stresses through
a change of its subnuclear localization, which, in turn, results
in a change of its transcriptional activity (unpublished data).
As to the role of MEF in the immune system, de¢ciency of
MEF expression in mice resulted in a signi¢cant reduction of
the number of NK-T cells in thymus. Simultaneously NK cell
development and function and perforin transcription were
also impaired. Thus it is clear that MEF is a key transcrip-
tional regulator in innate immune cells [21]. On the other
hand, in epithelial cells, based on our previous study, MEF
positively regulates the antimicrobial protein, lysozyme, at the
transcriptional level [20]. Therefore, our present data provide
evidence of the linkage between MEF and the antimicrobial
peptide HBD2. Taken together, it is implied that MEF also
plays important roles in innate immunity of epithelial cells.
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